Sunshine Lake Pharma’s shares fell in their trading debut in Hong Kong, as the city’s buzz over first-day trading took a ...

Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP.

With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.